{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:44:20Z","timestamp":1792485860229,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.trecan.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:01:15Z","timestamp":1751842875000},"page":"923-926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["IL-18 revives dysfunctional CAR-T cells"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2025.06.008_bb0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.06.008_bb0010","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2025.06.008_bb0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2025.06.008_bb0020","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1038\/s41467-023-42619-2","article-title":"Unlocking the potential of allogeneic V\u03b42 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR\/IL-15 engineering","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2025.06.008_bb0025","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2025.06.008_bb0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2023022293","article-title":"IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2025.06.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2025.06.008_bb0040","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2025.06.008_bb0045","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.trecan.2025.06.008_bb0050","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","article-title":"Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers","volume":"30","author":"Fischer-Riepe","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2025.06.008_bb0055","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.ymthe.2024.05.013","article-title":"Granzyme B-activated IL18 potentiates \u03b1\u03b2 and \u03b3\u03b4 CAR T cell immunotherapy in a tumor-dependent manner","volume":"32","author":"Hull","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2025.06.008_bb0060","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2025.06.008_bb0065","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2025.06.008_bb0070","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2025.06.008_bb0075","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41467-025-56270-6","article-title":"Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325001517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803325001517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:33:52Z","timestamp":1763015632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803325001517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2405803325001517"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2025.06.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-18 revives dysfunctional CAR-T cells","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}